Caffeine, the world's most widely used psychomotor stimulant, potentiates the antiparkinsonian effects of levodopa in preclinical models, as noted nearly 40 years ago. 1 The findings prompted early placebo-controlled crossover studies of caffeine as an adjunct to levodopa or a dopamine agonist in Parkinson disease (PD). 2, 3 No motor effect of caffeine was demonstrated other than exacerbation of dyskinesia. However, these small studies assessed caffeine at high doses (ϳ1,100 mg/day, the equivalent of ϳ8 cups of brewed coffee/day), at which most subjects reported restlessness and insomnia. By contrast, another small study reported that caffeine at a much lower dose of 100 mg/day helped improve freezing of gait, though tolerance to caffeine seemed to limit benefit. 4 In this issue of Neurology ® , Postuma et al. 5 report the results of a randomized controlled trial of caffeine as a treatment of excessive daytime sleepiness in PD. Although efficacy for improving wakefulness assessed under the primary outcome did not reach statistical significance (yielding Class I evidence against such an indication in PD), a secondary outcome analysis provided evidence in support of an antiparkinsonian motor effect of caffeine. Sixty-one subjects with PD with documented daytime sleepiness and moderate motor symptoms, treated with ϳ600 mg per day of levodopa on average, were randomized 1:1 to placebo vs 100 mg caffeine twice a day for 3 weeks before advancing to 200 mg twice daily for 3 more weeks. After 6 weeks, those in the caffeine group showed improvement relative to controls on a standard clinical scale of parkinsonian dysfunction (close to 5 points on the total Unified Parkinson's Disease Rating Scale [UPDRS]), including its objective motor component and subscores for bradykinesia and rigidity, with similar findings at 3 weeks on the lower dose.
Several limitations of the study, as discussed by the authors, include the exploratory nature of the motor findings given the primary hypothesis of a nonmotor benefit; the possibility of incomplete blinding; and the brevity of treatment, leaving open the question of tolerance to caffeine. Nevertheless, these findings are noteworthy, the first to suggest antiparkinsonian effects of caffeine in a randomized clinical trial.
This Class II evidence that motor function in PD can be improved by caffeine is bolstered by mechanistic and clinical advances identifying adenosine A 2A receptor antagonism as the molecular basis of caffeine's psychomotor stimulant properties, and as a promising antiparkinsonian strategy. The discovery by the early 1980s that caffeine likely acts through antagonism of adenosine receptors 6 coupled with caffeine's antiparkinsonian effects in animal models 1 accelerated research into the neurobiology and neurotherapeutic potential of adenosine receptor blockade. Enthusiasm for targeting adenosine A 2A receptors in particular as a candidate antiparkinsonian strategy grew after the colocalization of A 2A receptors with dopamine D 2 receptors in striatopallidal output neurons, where their opposing cellular influences account for antiparkinsonian actions of both A 2A antagonists and D 2 agonists. 6, 7 Moreover, the relatively restricted expression of CNS A 2A receptors to and within the striatum 7 (figure, A) suggests a low liability for neuropsychiatric side effects of A 2A antagonists, in contrast to existing nondopaminergic antiparkinsonian agents targeting much more widespread CNS receptors. Neuroimaging and behavioral data confirmed that caffeine indeed blocks striatal A 2A receptors (figure, B) , 8 which appear required for its motor stimulant properties (figure, C). 9 Caffeine's candidacy as an antiparkinsonian agent is strengthened further by progress made with several more specific A 2A antagonists (including istradefylline, preladenant, and tozadenant). Positive results have prompted ongoing phase II and III clinical trials of their antiparkinsonian potential. Epidemiologic and laboratory evidence that caffeine and specific A 2A antagonists may offer additional benefits of slowing the underlying neurodegenerative process or reducing the risk of dyskinesias, 7 while clinically untested, has helped justify a high level of investment in adenosine antagonism for PD.
Nevertheless, the findings of Postuma et al. 5 underscore the longstanding question of whether the greater selectivity for A 2A (over A 1 and other adenosine receptor subtypes) offered by adenosine antagonists in commercial development constitutes a clinically meaningful advantage over the relatively nonspecific adenosine antagonism of caffeine. Such benefits should be substantial to offset the unmatchable advantages of caffeine's long-term safety experience and cost. Moreover, as the authors note, their preliminary findings that caffeine improved total UPDRS score by 4 -5 points, if substantiated, may be comparable to UPDRS improvements achieved to date with specific A 2A antagonists.
There are theoretical disadvantages of caffeine and its greater likelihood for "off-target " effects. For example, caffeine classically produces tolerance to its motor stimulant actions; by contrast, preclinical studies of a specific A 2A antagonist failed to demonstrate tolerance to motor stimulant and antiparkinsonian effects. 10 Ultimately, headto-head comparisons may be required to distinguish the utility of A 2A -specific and mixed adenosine receptor antagonists for treating the motor symptoms or other features of PD. For the time being, the results of Postuma et al. 5 should encourage further investigation of a potential antiparkinsonian ("cruise control") benefit of caffeine without entirely discouraging pursuit of its putative alerting ("snooze patrol") action in PD. Although current data do not warrant a recommendation of caffeine as a therapeutic intervention in PD, they can reasonably be taken into consideration when discussing dietary caffeine use. 9 For details, see cited publications and references therein, from which panels are adapted with permission.
